<DOC>
	<DOCNO>NCT02875951</DOCNO>
	<brief_summary>A prospective , non-interventional , non-controlled multicenter observational study evaluate aspect pharmaceutical care treatment postmenopausal patient hormone-receptor positive , HER2-receptor negative , advanced breast cancer treat everolimus exemestane . The main objective study evaluate medication adherence postmenopausal , hormone-receptor positive , HER2-receptor negative , advanced breast cancer treat combination everolimus exemestane . Additionally , aspect pharmacotherapy , focus patient perspective , investigate : - Patient satisfaction treatment information - Patient satisfaction treatment - Health-related quality life - Treatment efficacy - Treatment-related toxicity - Patient follow-up oncologic team/general practitioner specialize home nurse This study reveal information necessary development pharmacotherapeutic care concept meet needs cancer patient treat oral anti-cancer drug long period .</brief_summary>
	<brief_title>Investigating Patient Satisfaction With Oral Anti-cancer Treatment Patients With Hormone-receptor Positive , HER2-receptor Negative , Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Postmenopausal woman , 18 year old Signed write informed consent Patient contact phone and/or email HR+ , HER2 advance metastatic breast cancer Recurrence progression follow nonsteroidal aromatase inhibitor Able swallow retain oral medication Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 Patients able understand Dutch French Symptomatic visceral metastatic disease Patients take investigational drug within 28 day 5 halflives , whichever short , prior recruitment Current use prohibit medication describe SPC Any serious unstable preexist medical condition , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent , compliance study procedure Hypersensitivity active substance excipients</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>